CHMP recommend update of market authorisation for everolimus (Votubia)

he CHMP did not recommend a licence extension to cover use in children from the age of 6 months as the error margin of the relevant study was too wide, however it agreed that the data from this study could be included in the medicine’s product information.

European Medicines Agency